DIAGNOS Inc. Poised for Parabolic Move, First of New Cardiovascular AI Applications Coming to Market. DIAGNOS Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) is a Canadian-based healthcare software technology company that pioneered 'Computer Assisted Retinal Analysis' (CARA), applying artificial intelligence to non-invasively test, identify, and classify patients at risk of vision loss (targeted at the diabetes market). Using the same retinal image from its CARA platform, DIAGNOS is now expanding its algorithmic technology into applications for the cardiovascular sector, a market that currently spends >US$500 Billion a year in drugs and services for cardiovascular and stroke issues. The first of its new revolutionary cardio applications is ready to hit the market, giving the Company a major competitive advantage in marketing that should see sales dramatically increase; DIAGNOS' hypertension application is set to come to market this Q3-2020 as an add-on to its CARA. Even more important though, in terms of potential, is its 'Stroke Predictor' application which is scheduled for a major 1,000 patient validation test at three major hospitals in Canada and USA -- positive results on the Stroke Predictor will redefine DIAGNOS INC. and translate into extreme share price revaluation for ADK.V. see
https://technologymarketwatch.com/adk.htm online